TUSTIN, CA--(Marketwire - February 3, 2011) - Jade Pharmaceuticals Inc., a China based pharmaceutical company and deconsolidated subsidiary of Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, reported today it has closed on $900,000 in bridge financing.